CRL Featured in Non-Animal Testing Market Outlook Through 2035
What happened
A newly published market research report spanning 2025 to 2035 profiles Charles River Laboratories alongside Labcorp and Eurofins Scientific in the animal testing and non-animal alternative testing sector. The report examines the competitive landscape and projected trajectory of the industry over the decade-long forecast window. Non-animal alternative methods are an expanding segment as regulatory pressure and scientific advances drive adoption across pharmaceutical and biotech clients. Charles River Laboratories operates across both traditional and emerging testing modalities.
The QL Read
With breadth at 57.3% advancing and CRL carrying a composite signal of 66/100 at $295.10, the decade-long market outlook provides additional context on longer-term industry demand dynamics. Watch for CRL management commentary on alternative-method revenue mix as the next concrete data point.